Dori Thomas-Karyat
Synthis
We are developing a novel immuno-oncology (IO) therapeutic that reserves immune suppression in metastatic melanoma patients who have failed immune checkpoint blockade.
Synthis
We are developing a novel immuno-oncology (IO) therapeutic that reserves immune suppression in metastatic melanoma patients who have failed immune checkpoint blockade.